Legal & General Group Plc Acquires New Shares in Grail, Inc. (NASDAQ:GRAL)

Legal & General Group Plc acquired a new stake in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 72,398 shares of the company's stock, valued at approximately $1,292,000. Legal & General Group Plc owned approximately 0.22% of Grail as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of GRAL. FNY Investment Advisers LLC bought a new stake in Grail during the 4th quarter valued at $26,000. Lindbrook Capital LLC acquired a new stake in shares of Grail in the 4th quarter worth about $28,000. Wellington Shields Capital Management LLC bought a new position in Grail in the 4th quarter valued at about $33,000. New York State Common Retirement Fund acquired a new position in Grail during the 4th quarter valued at about $59,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Grail during the 4th quarter valued at about $64,000.

Grail Stock Performance

Shares of GRAL stock traded down $0.09 during trading on Tuesday, hitting $36.81. The company's stock had a trading volume of 1,515,161 shares, compared to its average volume of 1,224,960. The business has a fifty day moving average of $30.83 and a 200-day moving average of $24.58. Grail, Inc. has a 52 week low of $12.33 and a 52 week high of $63.99.

Grail (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, topping analysts' consensus estimates of ($4.41) by $2.55. The company had revenue of $38.25 million during the quarter, compared to analysts' expectations of $35.33 million. As a group, sell-side analysts expect that Grail, Inc. will post -15.15 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on GRAL. Canaccord Genuity Group started coverage on Grail in a research report on Monday, April 21st. They issued a "buy" rating and a $32.00 price target for the company. Morgan Stanley raised their price target on shares of Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 18th.

Insider Buying and Selling at Grail

In other news, President Joshua J. Ofman sold 2,109 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.20, for a total transaction of $65,800.80. Following the transaction, the president now owns 559,673 shares of the company's stock, valued at $17,461,797.60. This represents a 0.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Ragusa sold 7,625 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.21, for a total value of $237,976.25. Following the transaction, the chief executive officer now owns 828,662 shares of the company's stock, valued at $25,862,541.02. The trade was a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,550 shares of company stock worth $360,436 over the last three months.

Grail Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.